JP5081807B2 - 補体−媒介疾患及び状態の処置のための新規なチオフェンスルホキシイミン - Google Patents
補体−媒介疾患及び状態の処置のための新規なチオフェンスルホキシイミン Download PDFInfo
- Publication number
- JP5081807B2 JP5081807B2 JP2008501978A JP2008501978A JP5081807B2 JP 5081807 B2 JP5081807 B2 JP 5081807B2 JP 2008501978 A JP2008501978 A JP 2008501978A JP 2008501978 A JP2008501978 A JP 2008501978A JP 5081807 B2 JP5081807 B2 JP 5081807B2
- Authority
- JP
- Japan
- Prior art keywords
- thiophene
- methylsulfanyl
- bromophenyl
- carboxyamidine
- sulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
- 230000001404 mediated effect Effects 0.000 title abstract description 19
- 230000000295 complement effect Effects 0.000 title description 25
- 201000010099 disease Diseases 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 173
- 230000024203 complement activation Effects 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 196
- -1 benzylthio Chemical group 0.000 claims description 146
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 77
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 210000000056 organ Anatomy 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 230000000451 tissue damage Effects 0.000 claims description 18
- 231100000827 tissue damage Toxicity 0.000 claims description 18
- 208000011580 syndromic disease Diseases 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 206010028417 myasthenia gravis Diseases 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 10
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 10
- 206010040070 Septic Shock Diseases 0.000 claims description 10
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 10
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 230000036303 septic shock Effects 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 9
- 230000006749 inflammatory damage Effects 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 238000002054 transplantation Methods 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 229910052717 sulfur Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 5
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 238000010322 bone marrow transplantation Methods 0.000 claims description 5
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- CEWVKBBBSKVINX-UHFFFAOYSA-N 1-methylsulfonyl-5-sulfonylcyclohexa-1,3-diene Chemical compound CS(=O)(=O)C1=CC=CC(=S(=O)=O)C1 CEWVKBBBSKVINX-UHFFFAOYSA-N 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 102000000503 Collagen Type II Human genes 0.000 claims description 4
- 108010041390 Collagen Type II Proteins 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000009386 Experimental Arthritis Diseases 0.000 claims description 4
- 208000001034 Frostbite Diseases 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 4
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
- KWHYFDZLKUXLJN-UHFFFAOYSA-N 2-(5-sulfonylcyclohexa-1,3-dien-1-yl)guanidine Chemical compound NC(=N)NC1=CC=CC(=S(=O)=O)C1 KWHYFDZLKUXLJN-UHFFFAOYSA-N 0.000 claims description 3
- YJRQBOOMJGYUPI-UHFFFAOYSA-N 4-methyl-2,3-dihydro-1,4-benzoxazine Chemical compound C1=CC=C2N(C)CCOC2=C1 YJRQBOOMJGYUPI-UHFFFAOYSA-N 0.000 claims description 3
- TXOWBBUBRITKNS-UHFFFAOYSA-N 4-sulfonylcyclohexa-1,5-diene-1-carboxylic acid Chemical compound OC(=O)C1=CCC(=S(=O)=O)C=C1 TXOWBBUBRITKNS-UHFFFAOYSA-N 0.000 claims description 3
- RFNMIIXJLZIGFH-UHFFFAOYSA-N 5-methyl-2-nitro-6-sulfonylcyclohexa-1,3-diene Chemical compound CC1C=CC([N+]([O-])=O)=CC1=S(=O)=O RFNMIIXJLZIGFH-UHFFFAOYSA-N 0.000 claims description 3
- QPGFOBZXEDNQGR-UHFFFAOYSA-N 5-sulfonyl-1-(trifluoromethyl)cyclohexa-1,3-diene Chemical compound FC(F)(F)C1=CC=CC(=S(=O)=O)C1 QPGFOBZXEDNQGR-UHFFFAOYSA-N 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 206010029240 Neuritis Diseases 0.000 claims description 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 3
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000005108 alkenylthio group Chemical group 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 3
- 206010040882 skin lesion Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 2
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 claims description 2
- DNHDDHKYVAJUAO-UHFFFAOYSA-N 5-methyl-2-methylsulfonyl-6-sulfonylcyclohexa-1,3-diene Chemical compound CC1C=CC(S(C)(=O)=O)=CC1=S(=O)=O DNHDDHKYVAJUAO-UHFFFAOYSA-N 0.000 claims description 2
- YSMLJJOMCIZNGL-UHFFFAOYSA-N 5-sulfonylcyclohexa-1,3-diene-1-carboxylic acid Chemical compound OC(=O)C1=CC=CC(=S(=O)=O)C1 YSMLJJOMCIZNGL-UHFFFAOYSA-N 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 206010052428 Wound Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000000162 organ preservation solution Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 abstract description 16
- 230000001154 acute effect Effects 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 7
- 208000017667 Chronic Disease Diseases 0.000 abstract description 6
- 239000000651 prodrug Substances 0.000 abstract description 5
- 229940002612 prodrug Drugs 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 203
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 141
- 238000006243 chemical reaction Methods 0.000 description 128
- 239000000243 solution Substances 0.000 description 116
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- 235000019439 ethyl acetate Nutrition 0.000 description 87
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 72
- 239000007787 solid Substances 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 56
- 238000005160 1H NMR spectroscopy Methods 0.000 description 52
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 46
- 239000012044 organic layer Substances 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 46
- 239000000460 chlorine Substances 0.000 description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 40
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 38
- 239000000047 product Substances 0.000 description 38
- 239000002904 solvent Substances 0.000 description 34
- 239000012267 brine Substances 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 27
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 24
- 239000011734 sodium Substances 0.000 description 24
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 23
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 23
- 238000000746 purification Methods 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 238000002953 preparative HPLC Methods 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 229910052786 argon Inorganic materials 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 101000933374 Gallus gallus Brain-specific homeobox/POU domain protein 3 Proteins 0.000 description 15
- HWBAROXGWFHSNY-UHFFFAOYSA-N 1-phenyl-1$l^{3}-iodinane Chemical compound C1CCCCI1C1=CC=CC=C1 HWBAROXGWFHSNY-UHFFFAOYSA-N 0.000 description 14
- 230000004154 complement system Effects 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000010626 work up procedure Methods 0.000 description 13
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 150000004702 methyl esters Chemical class 0.000 description 11
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 11
- 125000005555 sulfoximide group Chemical group 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 125000001841 imino group Chemical group [H]N=* 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 10
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229910021529 ammonia Inorganic materials 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000012131 assay buffer Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- DMVPDDNJDURHQR-UHFFFAOYSA-N tert-butyl 4-sulfonylcyclohexa-1,5-diene-1-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CCC(=S(=O)=O)C=C1 DMVPDDNJDURHQR-UHFFFAOYSA-N 0.000 description 8
- HLSHKIBATYEGMR-UHFFFAOYSA-N 6-cyanopyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(C#N)N=C1 HLSHKIBATYEGMR-UHFFFAOYSA-N 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 7
- 238000012746 preparative thin layer chromatography Methods 0.000 description 7
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 7
- AXARICBIQADTMK-UHFFFAOYSA-N 4-(3-bromophenyl)sulfinyl-5-chlorothiophene-2-carbonitrile Chemical compound S1C(C#N)=CC(S(=O)C=2C=C(Br)C=CC=2)=C1Cl AXARICBIQADTMK-UHFFFAOYSA-N 0.000 description 6
- 0 CC(Nc1cc(S(N=S(C2C=C(*3NC3N)SC2SC)(c2cccc(Br)c2)=O)(=O)=O)ccc1)=O Chemical compound CC(Nc1cc(S(N=S(C2C=C(*3NC3N)SC2SC)(c2cccc(Br)c2)=O)(=O)=O)ccc1)=O 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- CRMSRYXGZPIPFY-UHFFFAOYSA-N tert-butyl 5-sulfonylcyclohexa-1,3-diene-1-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(=S(=O)=O)C1 CRMSRYXGZPIPFY-UHFFFAOYSA-N 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- WHIYTPLNDQYIBZ-UHFFFAOYSA-N 4-bromo-5-nitrothiophene-2-carbonitrile Chemical compound [O-][N+](=O)C=1SC(C#N)=CC=1Br WHIYTPLNDQYIBZ-UHFFFAOYSA-N 0.000 description 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 5
- 102100022133 Complement C3 Human genes 0.000 description 5
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 5
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 5
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 5
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 description 5
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 5
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- BKXFEGNKFAVCQM-UHFFFAOYSA-N 4-bromo-5-chlorothiophene-2-carbonitrile Chemical compound ClC=1SC(C#N)=CC=1Br BKXFEGNKFAVCQM-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- HJHXMCYQJCTPCV-UHFFFAOYSA-N nitrosulfonylbenzene Chemical compound [O-][N+](=O)S(=O)(=O)C1=CC=CC=C1 HJHXMCYQJCTPCV-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 3
- WYDHOAWXGDVROE-UHFFFAOYSA-N 3-(2-phenylpropan-2-ylcarbamoyl)benzenesulfonyl chloride Chemical compound C=1C=CC=CC=1C(C)(C)NC(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 WYDHOAWXGDVROE-UHFFFAOYSA-N 0.000 description 3
- KSHOQKKCPJELBV-UHFFFAOYSA-N 3-bromo-2-chlorothiophene Chemical compound ClC=1SC=CC=1Br KSHOQKKCPJELBV-UHFFFAOYSA-N 0.000 description 3
- CQEFJGDLGWJIRV-UHFFFAOYSA-N 3-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 CQEFJGDLGWJIRV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 102100037483 POU domain, class 6, transcription factor 1 Human genes 0.000 description 3
- 101710196406 POU domain, class 6, transcription factor 1 Proteins 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- CWSVOVBBJJVZRN-UHFFFAOYSA-N [O-][N+](=O)C1=CC=CC(=S(=O)=O)C1 Chemical compound [O-][N+](=O)C1=CC=CC(=S(=O)=O)C1 CWSVOVBBJJVZRN-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 3
- FUEFNUGYRWQHTH-UHFFFAOYSA-N (2-nitrophenyl)methanesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1CS(Cl)(=O)=O FUEFNUGYRWQHTH-UHFFFAOYSA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- RZBGFGZNHVTAMU-UHFFFAOYSA-N 2-nitro-5-sulfonylcyclohexa-1,3-diene Chemical compound [O-][N+](=O)C1=CCC(=S(=O)=O)C=C1 RZBGFGZNHVTAMU-UHFFFAOYSA-N 0.000 description 2
- XGYIVEOJKIQXFB-UHFFFAOYSA-N 2-trimethylsilylethyl n-[3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(2-trimethylsilylethoxycarbonylamino)phenyl]carbamate Chemical compound CC1=CC(NC(=O)OCC[Si](C)(C)C)=CC(NC(=O)OCC[Si](C)(C)C)=C1B1OC(C)(C)C(C)(C)O1 XGYIVEOJKIQXFB-UHFFFAOYSA-N 0.000 description 2
- HNGQQUDFJDROPY-UHFFFAOYSA-N 3-bromobenzenethiol Chemical compound SC1=CC=CC(Br)=C1 HNGQQUDFJDROPY-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 2
- MEDQIURMEOFGNK-UHFFFAOYSA-N 4-(3-bromophenyl)sulfinyl-5-nitrothiophene-2-carbonitrile Chemical compound S1C(C#N)=CC(S(=O)C=2C=C(Br)C=CC=2)=C1[N+](=O)[O-] MEDQIURMEOFGNK-UHFFFAOYSA-N 0.000 description 2
- VVTSZQWGTDZBFV-UHFFFAOYSA-N 4-bromo-5-nitrothiophene-2-carbaldehyde Chemical compound [O-][N+](=O)C=1SC(C=O)=CC=1Br VVTSZQWGTDZBFV-UHFFFAOYSA-N 0.000 description 2
- UVIXTMKEEWQWCZ-UHFFFAOYSA-N 5-amino-4-(3-bromophenyl)sulfanylthiophene-2-carbonitrile Chemical compound S1C(C#N)=CC(SC=2C=C(Br)C=CC=2)=C1N UVIXTMKEEWQWCZ-UHFFFAOYSA-N 0.000 description 2
- DMNUIXCWPWQAOW-UHFFFAOYSA-N 5-bromo-4-(3-bromophenyl)sulfanylthiophene-2-carbonitrile Chemical compound S1C(C#N)=CC(SC=2C=C(Br)C=CC=2)=C1Br DMNUIXCWPWQAOW-UHFFFAOYSA-N 0.000 description 2
- ITIGGKJZXRZEMP-UHFFFAOYSA-N 5-bromo-4-(3-bromophenyl)sulfinylthiophene-2-carbonitrile Chemical compound S1C(C#N)=CC(S(=O)C=2C=C(Br)C=CC=2)=C1Br ITIGGKJZXRZEMP-UHFFFAOYSA-N 0.000 description 2
- WMHSQCDPPJRWIL-UHFFFAOYSA-N 6-cyanopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)N=C1 WMHSQCDPPJRWIL-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- RORDOIIFUKGITK-UHFFFAOYSA-N FC(C(=O)O)(F)F.SC1=C(SC=C1)C(=N)N Chemical compound FC(C(=O)O)(F)F.SC1=C(SC=C1)C(=N)N RORDOIIFUKGITK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 102100026553 Mannose-binding protein C Human genes 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000026137 Soft tissue injury Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 208000005707 acquired angioedema Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000004074 complement inhibitor Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GZFNODRFANEVDV-UHFFFAOYSA-N methyl 3-(2-methyl-4-nitrophenyl)benzenesulfinate Chemical compound COS(=O)C1=CC=CC(C=2C(=CC(=CC=2)[N+]([O-])=O)C)=C1 GZFNODRFANEVDV-UHFFFAOYSA-N 0.000 description 2
- ZZIFYVOKYRWVGL-UHFFFAOYSA-N methyl 3-[2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]benzenesulfinate Chemical compound COS(=O)C1=CC=CC(C=2C(=CC(NC(=O)OC(C)(C)C)=CC=2)C)=C1 ZZIFYVOKYRWVGL-UHFFFAOYSA-N 0.000 description 2
- QNGDLQBWPLJQKQ-UHFFFAOYSA-N methyl 3-bromobenzenesulfinate Chemical compound COS(=O)C1=CC=CC(Br)=C1 QNGDLQBWPLJQKQ-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- VEHOEHLROPOFBF-UHFFFAOYSA-N n-[(4-bromo-5-nitrothiophen-2-yl)methylidene]hydroxylamine Chemical compound ON=CC1=CC(Br)=C([N+]([O-])=O)S1 VEHOEHLROPOFBF-UHFFFAOYSA-N 0.000 description 2
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- JQJOGAGLBDBMLU-UHFFFAOYSA-N pyridine-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=N1 JQJOGAGLBDBMLU-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- AWLHDQBQCCRNJH-UHFFFAOYSA-N tert-butyl 3-sulfamoylbenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC(S(N)(=O)=O)=C1 AWLHDQBQCCRNJH-UHFFFAOYSA-N 0.000 description 2
- SRRVWIMYGBUKMI-UHFFFAOYSA-N tert-butyl 4-sulfamoylbenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(S(N)(=O)=O)C=C1 SRRVWIMYGBUKMI-UHFFFAOYSA-N 0.000 description 2
- WHDDTFLOFQTWTQ-UHFFFAOYSA-N tert-butyl n-[4-[3-(2-chloro-5-cyanothiophen-3-yl)sulfinylphenyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC=CC(S(=O)C2=C(SC(=C2)C#N)Cl)=C1 WHDDTFLOFQTWTQ-UHFFFAOYSA-N 0.000 description 2
- UQJXXWHAJKRDKY-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-methylsulfanylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(SC)=NC(=O)OC(C)(C)C UQJXXWHAJKRDKY-UHFFFAOYSA-N 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- UFDULEKOJAEIRI-UHFFFAOYSA-N (2-acetyloxy-3-iodophenyl) acetate Chemical compound CC(=O)OC1=CC=CC(I)=C1OC(C)=O UFDULEKOJAEIRI-UHFFFAOYSA-N 0.000 description 1
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- YJFLFKPAQHMYHZ-UHFFFAOYSA-N 1,2-dibromo-3-[(2,3-dibromophenyl)disulfanyl]benzene Chemical compound BrC1=CC=CC(SSC=2C(=C(Br)C=CC=2)Br)=C1Br YJFLFKPAQHMYHZ-UHFFFAOYSA-N 0.000 description 1
- DMFPQQCIQDWBJK-UHFFFAOYSA-N 1,3-thiazole-5-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CN=CS1 DMFPQQCIQDWBJK-UHFFFAOYSA-N 0.000 description 1
- UQXIBURWCLDEAR-UHFFFAOYSA-N 1-(3-nitrophenyl)sulfonyl-1$l^{3}-iodinane Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)I2CCCCC2)=C1 UQXIBURWCLDEAR-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- KXGSEDAILWXFFD-UHFFFAOYSA-N 2-(2-bromo-4-methylphenoxy)-n-[4-[(2,6-dimethylpyrimidin-4-yl)sulfamoyl]phenyl]acetamide Chemical compound BrC1=CC(C)=CC=C1OCC(=O)NC1=CC=C(S(=O)(=O)NC=2N=C(C)N=C(C)C=2)C=C1 KXGSEDAILWXFFD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- UAPXGQGQLFOWOC-UHFFFAOYSA-N 2-methyl-5-methylsulfonylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(C)(=O)=O)C=C1S(Cl)(=O)=O UAPXGQGQLFOWOC-UHFFFAOYSA-N 0.000 description 1
- GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RCHRDLRRWCHVDP-UHFFFAOYSA-N 2-trimethylsilylethyl N-[3-methyl-2-phenyl-5-(2-trimethylsilylethoxycarbonylamino)phenyl]carbamate Chemical compound CC1=CC(NC(=O)OCC[Si](C)(C)C)=CC(NC(=O)OCC[Si](C)(C)C)=C1C1=CC=CC=C1 RCHRDLRRWCHVDP-UHFFFAOYSA-N 0.000 description 1
- BTEQQLFQAPLTLI-UHFFFAOYSA-N 2-trimethylsilylethyl carbonochloridate Chemical compound C[Si](C)(C)CCOC(Cl)=O BTEQQLFQAPLTLI-UHFFFAOYSA-N 0.000 description 1
- NVZBCBJNRFKVHB-UHFFFAOYSA-N 3-(1,3-oxazol-5-yl)benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(C=2OC=NC=2)=C1 NVZBCBJNRFKVHB-UHFFFAOYSA-N 0.000 description 1
- IZKQGEKIDKCBSX-UHFFFAOYSA-N 3-(5-methyl-1,3,4-oxadiazol-2-yl)benzenesulfonyl chloride Chemical compound O1C(C)=NN=C1C1=CC=CC(S(Cl)(=O)=O)=C1 IZKQGEKIDKCBSX-UHFFFAOYSA-N 0.000 description 1
- ONCAZCNPWWQQMW-UHFFFAOYSA-N 3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC(S(Cl)(=O)=O)=C1 ONCAZCNPWWQQMW-UHFFFAOYSA-N 0.000 description 1
- BCZHCWCOQDRYGS-UHFFFAOYSA-N 3-bromothiophene-2-carbaldehyde Chemical compound BrC=1C=CSC=1C=O BCZHCWCOQDRYGS-UHFFFAOYSA-N 0.000 description 1
- LMRKXSDOAFUINK-UHFFFAOYSA-N 3-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 LMRKXSDOAFUINK-UHFFFAOYSA-N 0.000 description 1
- XWEBTVZIZWEJOO-UHFFFAOYSA-N 3-chlorosulfonylbenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 XWEBTVZIZWEJOO-UHFFFAOYSA-N 0.000 description 1
- FPGDDWCTBDGPAD-UHFFFAOYSA-N 3-chlorothiophene-2-carbonitrile Chemical compound ClC=1C=CSC=1C#N FPGDDWCTBDGPAD-UHFFFAOYSA-N 0.000 description 1
- BHNRGBRMCNHNQD-UHFFFAOYSA-N 3-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(C#N)=C1 BHNRGBRMCNHNQD-UHFFFAOYSA-N 0.000 description 1
- YINSMSZSYILWFR-UHFFFAOYSA-N 3-methylsulfanylthiophene-2-carboximidamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CSC=1C=CSC=1C(N)=N YINSMSZSYILWFR-UHFFFAOYSA-N 0.000 description 1
- MBNPJRQKQLLRIS-UHFFFAOYSA-N 3-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC(N)=C1 MBNPJRQKQLLRIS-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- VXWKXTVJLVEIIY-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(2-methyl-4-nitrophenyl)-1,3,2-dioxaborolane Chemical compound CC1=CC([N+]([O-])=O)=CC=C1B1OC(C)(C)C(C)(C)O1 VXWKXTVJLVEIIY-UHFFFAOYSA-N 0.000 description 1
- PTGYPJXVQUVREU-UHFFFAOYSA-N 4-bromo-5-chlorothiophene-2-carbaldehyde Chemical compound ClC=1SC(C=O)=CC=1Br PTGYPJXVQUVREU-UHFFFAOYSA-N 0.000 description 1
- PTCSSXYPZOFISK-UHFFFAOYSA-N 4-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 PTCSSXYPZOFISK-UHFFFAOYSA-N 0.000 description 1
- PQOZDBIEDQALFA-UHFFFAOYSA-N 4-methyl-2,3-dihydro-1,4-benzoxazine-7-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2N(C)CCOC2=C1 PQOZDBIEDQALFA-UHFFFAOYSA-N 0.000 description 1
- OQFYBGANSUNUAO-UHFFFAOYSA-N 4-methyl-3-nitrobenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1[N+]([O-])=O OQFYBGANSUNUAO-UHFFFAOYSA-N 0.000 description 1
- DMTDVEQHTBNMHR-UHFFFAOYSA-N 4-methyl-n-(1-phenyl-1$l^{3}-iodinan-2-ylidene)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N=C1I(C=2C=CC=CC=2)CCCC1 DMTDVEQHTBNMHR-UHFFFAOYSA-N 0.000 description 1
- QWKKYJLAUWFPDB-UHFFFAOYSA-N 4-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 QWKKYJLAUWFPDB-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- MGYGFNQQGAQEON-UHFFFAOYSA-N 4-tolyl isocyanate Chemical compound CC1=CC=C(N=C=O)C=C1 MGYGFNQQGAQEON-UHFFFAOYSA-N 0.000 description 1
- TURGMVYIESHZBE-UHFFFAOYSA-N 5-bromo-6-chloropyridine-3-sulfonyl chloride Chemical compound ClC1=NC=C(S(Cl)(=O)=O)C=C1Br TURGMVYIESHZBE-UHFFFAOYSA-N 0.000 description 1
- VRJSCNPHNHSZJC-UHFFFAOYSA-N 5-methylsulfanylthiophene-2-carboximidamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CSC1=CC=C(C(N)=N)S1 VRJSCNPHNHSZJC-UHFFFAOYSA-N 0.000 description 1
- VTILWYBQQRECER-UHFFFAOYSA-N 5-sulfonylcyclohexa-1,3-diene Chemical compound O=S(=O)=C1CC=CC=C1 VTILWYBQQRECER-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- HSCADQQUNJBUFH-UHFFFAOYSA-N BCc1cccc(SSc2cc(Br)ccc2)c1 Chemical compound BCc1cccc(SSc2cc(Br)ccc2)c1 HSCADQQUNJBUFH-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- KOHJFXNLLRIKGG-UHFFFAOYSA-N C1=C(SC(=C1Br)Cl)NC(=O)O Chemical compound C1=C(SC(=C1Br)Cl)NC(=O)O KOHJFXNLLRIKGG-UHFFFAOYSA-N 0.000 description 1
- XDPUKUMVJXBDJY-UHFFFAOYSA-N CSc([s]c(C(N)=N)c1)c1S(c1cccc(Br)c1)(=N)=O Chemical compound CSc([s]c(C(N)=N)c1)c1S(c1cccc(Br)c1)(=N)=O XDPUKUMVJXBDJY-UHFFFAOYSA-N 0.000 description 1
- DXYZUTGTUXHQKZ-UHFFFAOYSA-N CSc([s]c(C(N)=O)c1)c1S(c1cccc(Br)c1)(=N)=O Chemical compound CSc([s]c(C(N)=O)c1)c1S(c1cccc(Br)c1)(=N)=O DXYZUTGTUXHQKZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DICZKMUIEAGVNJ-UHFFFAOYSA-N Cc(cc1)ccc1S(N=S(c1c(SC)[s]c(C(N)=N)c1)(c1cccc(-c2c(C)cccc2)c1)=O)(=O)=O Chemical compound Cc(cc1)ccc1S(N=S(c1c(SC)[s]c(C(N)=N)c1)(c1cccc(-c2c(C)cccc2)c1)=O)(=O)=O DICZKMUIEAGVNJ-UHFFFAOYSA-N 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 101000911993 Ovis aries CD59 glycoprotein Proteins 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- AJGVZXCPXDYLDU-UHFFFAOYSA-N [O-][N+](c(cccc1)c1S(/N=[I]\c1ccccc1)(=O)=O)=O Chemical compound [O-][N+](c(cccc1)c1S(/N=[I]\c1ccccc1)(=O)=O)=O AJGVZXCPXDYLDU-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- XEFCWBLINXJUIV-UHFFFAOYSA-N acetic acid;iodobenzene Chemical compound CC(O)=O.CC(O)=O.IC1=CC=CC=C1 XEFCWBLINXJUIV-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 230000008993 bowel inflammation Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- RRTNVDUNFNWLOK-UHFFFAOYSA-N bromobenzene;methanesulfinic acid Chemical compound CS(O)=O.BrC1=CC=CC=C1 RRTNVDUNFNWLOK-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005887 cellular phagocytosis Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- DXNQRSHWTHCVFM-UHFFFAOYSA-M copper trifluoromethanesulfonate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F DXNQRSHWTHCVFM-UHFFFAOYSA-M 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- JMPVESVJOFYWTB-UHFFFAOYSA-N dipropan-2-yl carbonate Chemical compound CC(C)OC(=O)OC(C)C JMPVESVJOFYWTB-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- TZURZEGRBVDGHY-UHFFFAOYSA-N formic acid S-methylthiohydroxylamine Chemical compound C(=O)O.CSN TZURZEGRBVDGHY-UHFFFAOYSA-N 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000054960 human MASP2 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- RYEXTBOQKFUPOE-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].CC[CH2-] RYEXTBOQKFUPOE-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- YWQXGWNJTLSZKY-UHFFFAOYSA-N methyl 2-bromobenzenesulfinate Chemical compound COS(=O)C1=CC=CC=C1Br YWQXGWNJTLSZKY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- PGKXMGKKTKQTFT-UHFFFAOYSA-N n-[4-(3-bromo-4-methoxyphenyl)-1,3-thiazol-2-yl]acetamide Chemical compound C1=C(Br)C(OC)=CC=C1C1=CSC(NC(C)=O)=N1 PGKXMGKKTKQTFT-UHFFFAOYSA-N 0.000 description 1
- IADJFFRYWBYPAR-UHFFFAOYSA-N n-methylsulfonyl-n-phenylmethanesulfonamide Chemical compound CS(=O)(=O)N(S(C)(=O)=O)C1=CC=CC=C1 IADJFFRYWBYPAR-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- VIVPWOMJFLICOZ-UHFFFAOYSA-N pyridine-3-sulfonyl chloride;hydrochloride Chemical compound Cl.ClS(=O)(=O)C1=CC=CN=C1 VIVPWOMJFLICOZ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JJXOIFHXNBFRNV-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JJXOIFHXNBFRNV-UHFFFAOYSA-N 0.000 description 1
- DPTOGGPXQUWLNC-UHFFFAOYSA-N tert-butyl N-(3-methylsulfanylthiophen-2-yl)carbamate Chemical compound C(C)(C)(C)OC(NC=1SC=CC1SC)=O DPTOGGPXQUWLNC-UHFFFAOYSA-N 0.000 description 1
- QTXXTRMGTVEBIN-UHFFFAOYSA-N tert-butyl n-thiophen-2-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CS1 QTXXTRMGTVEBIN-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Description
発明の背景
してC3a及びC3bを形成させる(非特許文献3;及び特許文献2)。古典的及び第二経路の両方は個別にC3コンバーターゼの生産を誘導してC3をC3bに変換することができ、その生成は補体経路の中心的事象である。C3bは好中球、好酸球、単球及びマクロファージ上に存在するC3b受容体に結合し、それにより末端ライシス補体配列、C5−C9を活性化する(非特許文献2)。
本発明は、式I:
Zは−CO−、−SO2−、−SO2CH2−、−COCH2−、−CONH−又は直接結合であり、
ここでカルボニル炭素又は硫黄は窒素に結合しており;
QはC1−4アルキル、ハロ、アミノ、C1−6アルキルチオ、C2−6アルケニルチオ、C1−6アルコキシ、トリフルオロメチル、メチルスルホニル又はベンジルチオであり;
R1は水素、C1−4アルキル、アリール、ヘテロアリール、ベンゾ縮合ヘテロアリール、ベンゾ縮合ヘテロシクリルであり、水素を除くそれらはいずれも場合により:グアニジニル、ハロゲン、−CF3、−CN、−NO2、−NRdCORe、−CONRdRe、−NRdSO2Re、−SO2NRdRe、−NRdCONHRe、−Rd、−NRdRe、−CO2Rd、−SO2Rd又は1個のRdで置換されていることができるヘテロシクリルから独立して選ばれる1もしくは2個の置換基で置換されていることができ;
R2は水素、ハロゲン、アリール又はヘテロアリールであり、ここでアリール又はヘテロアリールは場合により:C(1−4)アルキル、−NRfRg、グアニジニルから独立して選ばれる最高で3個の置換基で置換されていることができ;
Aはアリール又はヘテロアリールであり;
Ra、Rb、Rc、Rd、Re、Rf及びRgは独立して水素、C1−4アルキル、C6−10アリール、C1−4ヒドロキシアルキル、C1−4アミノアルキル、モノ(C1−4)アルキルアミノ(C2−6)アルキル、ジ(C1−4)アルキルアミノ(C2−6)アルキル、カルボキシ(C1−4)アルキル、シアノ、ニトロ、アミノ、C1−4アルコキシ、ヒドロキシ又は−CO2Rwであり、ここで
Rwは水素、ヒドロキシ、C1−4アルコキシ、シアノ、C1−4アルコキシカルボニル、C1−4アルキル、C3−8シクロアルキル、フェニル又はベンジルである]
のラセミ又はホモキラル化合物あるいはその溶媒和物、水和物、製薬学的に許容され得る塩又はプロドラッグに関する。
Zは−CO−、−SO2−、−SO2CH2−、−COCH2−、−CONH−又は直接結合であり、
ここでカルボニル炭素又は硫黄は窒素に結合しており;
QはC1−4アルキル、ハロ、アミノ、C1−6アルキルチオ、C2−6アルケニルチオ、C1−6アルコキシ、トリフルオロメチル、メチルスルホニル又はベンジルチオであり;
R1は水素、C1−4アルキル、アリール、ヘテロアリール、ベンゾ縮合ヘテロアリール、ベンゾ縮合ヘテロシクリルであり、水素を除くそれらはいずれも場合により:グアニジニル、ハロゲン、−CF3、−CN、−NO2、−NRdCORe、−CONRdRe、−NRdSO2Re、−SO2NRdRe、−NRdCONHRe、−Rd、−NRdRe、−CO2Rd、−SO2Rd又は1個のRdで置換されていることができるヘテロシクリルから独立して選ばれる1もしくは2個の置換基で置換されていることができ;
R2は水素、ハロゲン、アリール又はヘテロアリールであり、ここでアリール又はヘテロアリールは場合により:C(1−4)アルキル、−NRfRg、グアニジニルから独立して選ばれる最高で3個の置換基で置換されていることができ;
Aはアリール又はヘテロアリールであり;
Ra、Rb、Rc、Rd、Re、Rf及びRgは独立して水素、C1−4アルキル、C6−10アリール、C1−4ヒドロキシアルキル、C1−4アミノアルキル、モノ(C1−4)アルキルアミノ(C2−6)アルキル、ジ(C1−4)アルキルアミノ(C2−6)アルキル、カルボキシ(C1−4)アルキル、シアノ、ニトロ、アミノ、C1−4アルコキシ、ヒドロキシ又は−CO2Rwであり、ここで
Rwは水素、ヒドロキシ、C1−4アルコキシ、シアノ、C1−4アルコキシカルボニル、C1−4アルキル、C3−8シクロアルキル、フェニル又はベンジルである]
を有するか、又はその溶媒和物、水和物、製薬学的に許容され得る塩又はプロドラッグである。
Aがフェニルである式Iの化合物を含む。
−2H−ベンゾ[1,4]オキサジン、ベンズイミダゾリル、ベンゾフラニル、インドリル、ベンゾチオフェニル又は1,3,4オキサジアゾリルから選ばれ、水素を除くそれらはいずれも場合により:グアニジニル、ハロゲン、−CF3、−CN、−NO2、NRdCORe、NRdSO2Re、NRdCONHRe、Rd、NH2、CO2Re、SO2Rd、ヘテロシクリルから独立して選ばれる1もしくは2個の置換基で置換されていることができる式Iの化合物を含む。
それのみで又は他の基の一部として本明細書で用いられる「アルキル」という用語は、最高で12個の炭素の直鎖及び分枝鎖の両方の基、例えばメチル、エチル、プロピル、イソプロピル、ブチル、t−ブチル、イソブチル、ペンチル、ヘキシル、イソヘキシル、ヘプチル、4,4−ジメチルペンチル、オクチル、2,2,4−トリメチルペンチル、ノニル、デシル、ウンデシル、ドデシルを指す。
用語は、それぞれ1〜6個の炭素原子を有する2個のアルキル基で置換されたアミノ基を指す。
公式国民医薬品集(official National Formulary)又は合衆国薬局方(United States Pharmacopoeia)又はそれらへの補遺(supplement)において認められ、
人間又は他の動物における疾患又は他の状態の診断において、あるいは疾患の治癒、軽減、処置又は予防における使用を目的とするか、あるいは
人間又は他の動物の体の構造又はいずれかの機能に影響を与えることを目的とし、人間又は他の動物の体内もしくは体上で化学作用を介してその意図される本来の目的を達成せず、且つその意図される本来の目的の達成のために代謝されることに依存しない
機器、装置、器具、機械、仕掛け、移植片、試験管内試薬あるいは構成部品又は付属品を含む他の類似のもしくは関連する製品を指す。
略語:
AcOH 酢酸
AlMe3 トリメチルアルミニウム
Boc t−ブチルオキシカルボニル、また、tBoc
Boc2O 二炭酸ジ−tert−ブチル
tBuONO 2−メチル−2−ニトロソオキシ−プロパン
m−CPBA m−クロロ過安息香酸
Cu(OTf)2 トリフルオロメタンスルホン酸銅(II)
DCM ジクロロメタン
DIEA ジイソプロピルエチルアミン
DIC ジイソプロピルカーボネート
DME ジメトキシエタン
DMAP−樹脂 4−ジメチルアミノピリジン−改質(modified)樹脂
DMAP 4−ジメチルアミノピリジン
DMF ジメチルホルムアミド
DMSO ジメチルスルホキシド
DTNB 5,5’−ジチオ−ビス(2−ニトロ安息香酸)
ESI−MS エレクトロスプレーイオン化質量スペクトル
Et2O ジエチルエーテル
Et3N トリエチルアミン
EtOAc 酢酸エチル
HEPES 4−(2−ヒドロキシエチル)ピペラジン−1−エタンスルホ
ン酸
HPLC 高圧液体クロマトグラフィー
LDA リチウムジイソプロピルアミン
MeOH メタノール
NaOMe ナトリウムメトキシド
NaSMe ナトリウムメタンチオラート
NMR 核磁気共鳴
PCC クロロクロム酸ピリジニウム
Pd(dppf)Cl2 ジクロロ(1,1ビス(ジフェニルホスフィノ)フェロセン)
パラジウム(II)
Pd(PPh3)4 テトラキストリフェニルホスフィンPd0
PhI(OAc)2 ヨードベンゼンジアセテート
iPrMgCl イソプロピルマグネシウムクロリド
RP−HPLC 逆相高圧液体クロマトグラフィー
RT 室温
rt 保持時間
TFA トリフルオロ酢酸
TBAF フッ化テトラブチルアンモニウム
TEA トリエチルアミン
THF テトラヒドロフラン
TLC 薄層クロマトグラフィー
作用に起因する。敗血症性ショックにおいて、カリクレイン・キニン系の成分は枯渇し、この系の活性化を示唆する。これは心原性ショックではそうでなく、カリクレイン・キニン系が敗血症性ショックにおける中心的存在であることを示唆する(Martinez−Brotons F.et al.,Thromb.Haemostas.58:709−713(1987))。敗血症性ショック、DICおよび低血圧をもたらす実際の事象は確立されていないが、多数の生理系の様々な成分間の既知の相互作用は、接触経路の活性化が敗血症性ショックの状態、多臓器不全および死をもたらし得ることを示唆する(Bone,R.C.,Arch.Intern.Med.152:1381−1389(1992);Colman,R.W.,New Engl.J.Med.320:1207−1209(1989))。接触活性化経路はまた、フィブリン沈着および溶解の両方、ならびに好中球活性化を引き起こすこと、補体の活性化および血圧の調節にも関与する。
、内皮下層の白血球浸潤が、粘着血小板により潜在的に触媒作用を受け;そしてb)C5b−9複合体の膜沈着をもたらす局所的血管内補体活性化が冠状血管閉塞に付随して起こり、そして梗塞と関連する心筋障害の最終的程度に影響を及ぼし得るという考察により強調される。
哺乳類におけるC1sプロテアーゼ機能を阻害するために有効な量の式Iの化合物および製薬学的に許容しうる担体もしくは希釈剤を含んでなる、補体に媒介される病状を処置するための製薬学的組成物は、本発明の範囲内である。
workup)によりブロモ−ベンゼンスルフィン酸メチルエステルを生成せしめる。
いずれも場合により置換されていてもよい、フェニル、ナフチル、ピリジル、イミダゾリル、チアゾリル、フラニル、チエニル、ベンゾチアゾリル、ピラゾリル、ピリミジニル、ベンズイミダゾリル、ベンゾフラニル、インドリルもしくはベンゾチオフェニルのような異なるアリールチオールを使用できることは、当業者により認識される。
(スルホキシミンの製造のための一般的方法)
4−[S−(3−ブロモフェニル)−N−(2−ニトロベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(3−アセトアミドベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(3−{N,N−ビスメタンスルホニル}アミノベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
tert−ブチルエステル((実施例34:段階b)10.0mg,0.015mmol)の溶液をトリエチルアミン(4.3mL,0.031mmol)およびメタンスルホニルクロリド(1.4mL,0.019mmol)で処理した。反応物を室温で1.5h攪拌した。溶媒を真空中で蒸発させた。残留物をCH2Cl2(1.5mL)に溶解し、そしてトリフルオロ酢酸(250mL)で室温で1.5h処理した。溶媒を真空中で蒸発させた。分取HPLC(30分にわたって0.1%TFA/水中10〜50%のアセトニトリル)により4−[S−(3−ブロモフェニル)−N−(3−{N,N−ビスメタンスルホニルアミノ}ベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩(7.0mg,72%)を無色のガラス状固体として生成せしめた。1H NMR(CD3OD):δ8.346(s,1H),8.139(t,1H,J=2.0Hz),8.026−7.986(m,2H),7.941(d,1H,J=8.0Hz),7.907(d,1H,J=8.0Hz),7.742(d,1H,J=8.0Hz),7.635(t,1H,J=8.0Hz),7.562(t,1H,J=8.0Hz),3.512(s,6H),2.711(s,3H)。C20H21BrN4O7S6:701.70(M+1)実測値700.9/702.8。
4−[S−(3−ブロモフェニル)−N−(3−ウレイドベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(3−メタンスルホンアミドベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−{3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−ベンゼン−スルホニル}スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−{3−(オキサゾール−5−イル−ベンゼン−スルホニル}スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−[3−(2−アミノ−4−グアニジノ−6−メチル−フェニル)フェニル]−N−(4−ウレイドベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−p−トリル−ホルムアミド]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
ノ]−5−メチルスルファニル−チオフェン−2−カルバミン酸tert−ブチルエステル(実施例24:段階j)20.0mg,0.041mmol)の溶液をジイソプロピルエチルアミン(100mL,0.574mmol)および1−イソシアナト−4−メチルベンゼン(400mLのテトラヒドロフラン中0.25M溶液,0.751mmol)で室温で2h処理した。反応物をEtOAc(50mL)で希釈し、そしてクエン酸(3x10mL)、NaHCO3(2x10mL)およびブライン(20mL)で洗浄した。有機層をNa2SO4上で乾燥させ、そして真空中で濃縮した。残留物をCH2Cl2(3mL)に溶解し、そしてトリフルオロ酢酸(3mL)で室温で2h処理した。溶媒を真空中で蒸発させた。分取HPLC(40分にわたって0.1%TFA/水中10〜55%のアセトニトリル)により表題化合物(5.2mg,25%)を無色のガラス状固体として生成せしめた。1H NMR(CD3OD):δ8.43(s,1H),8.394(s,1H),8.16(d,1H,J=8.0Hz),7.92(d,1H,J=8.0Hz),7.58(t,1H,J=8.0Hz),7.34(d,2H,J=8.0Hz),7.09(d,2H,J=8.8Hz),2.72(s,3H),2.29(s,3H)。C20H19BrN4O2S3:523.49(M+1);実測値:522.7/524.6。
4−[S−(3−ブロモフェニル)−N−ベンズアミド]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−3−ニトロ−ベンズアミド]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−3−アミノ−ベンズアミド]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(フェニルメタン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(メタンスルホニル)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−({2−アミノフェニル}メタン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−[3−(2−アミノ−4−グアニジノ−6−メチル−フェニル)フェニル]−N−(3−ウレイドベンゼン−スルホニル)スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
−ニトロベンゼン)−スルホキシミノ]−5−クロロ−チオフェン−2−カル
ボニトリル
4−[S−(3−ブロモ−ベンゼンスルホニル)−N−(m−スルホニル安息香酸)−
スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモ−ベンゼンスルホニル)−N−(p−スルホニル安息香酸)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
実施例19:段階dにおけるような方法に従った。反応混合物をRTまで温め、そして一晩攪拌した。翌日、反応混合物を−78℃に冷却し、そしてメタノール中0.1MのNaSMe(764mL,0.076mmol)を加えた。反応混合物を−78℃で2時間攪拌し、飽和NaHCO3でクエンチし、そして酢酸エチルに抽出した。有機層を飽和NaHCO3、水およびブラインで洗浄し、硫酸マグネシウム上で乾燥させ、濾過し、そして真空中で濃縮して表題化合物を黄色の油(47.7mg,48%の収率)として生成せしめた。ESI−MS(m/z):C24H25BrN2O6S4の計算値:645.0(M+1);実測値:644.7。
4−[S−(3−ブロモフェニル)−N−(2−ピリジンスルホニル)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(m−スルホニルピリジル)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩の合成
4−[S−(3−ブロモフェニル)−N−(フェニル)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩の合成
よび精製により表題化合物を白色の固体(1.7mg,50%の収率)として生成せしめた。1H−NMR(CD3OD):δ8.34(s,1H),8.29−8.31(m,1H),8.13(dm,1H,J=8.0Hz),7.84(dm,1H,J=8.0Hz),7.51(t,1H,J=8.0Hz),7.11−7.19(m,4H),6.92−6.97(m,1H)および2.69(s,3H)。ESI−MS(m/z):C18H16BrN3OS3の計算値:466.0(M+1);実測値:465.9。
4−[S−(3−ブロモフェニル)−スルホキシミノ]−5−メチルスルファニル−チオフェン−2−カルバミン酸tert−ブチルエステル
びトリエチルアミン(無水,11.2mL,80.36mmol)をアセトニトリル(無水,250mL)中の4−ブロモ−5−クロロ−チオフェン−2−カルバルデヒド(実施例24:段階a,10.63g,47.14mmol)の0℃溶液に加えた。反応混合物を室温まで温め、そして1時間攪拌した。無水フタル酸を加え、そして反応混合物を80℃に一晩加熱した。混合物を室温まで冷却し、酢酸エチル(400mL)で希釈し、そして水性クエン酸、飽和NaHCO3、水およびブラインで洗浄した。有機層を硫酸マグネシウム上で乾燥させ、濾過し、真空中で濃縮し、そしてカラムクロマトグラフィー(シリカゲル,5%の酢酸エチル/ヘキサン)により精製して表題化合物を淡黄色の固体(9.76g,93%の収率)として生成せしめた。1H−NMR(CDCl3):δ7.47(s,1H)。
−2−カルボニトリル
ルファニル−チオフェン−2−カルボキサミジン
4−[S−(3−ブロモフェニル)−N−トシルスルホキシミノ]−5−メチルスルフ
ァニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
)−チオフェン−2−カルボニトリル(実施例25:段階h;322mg,0.95mmol)および(N−(p−トルエンスルホニル)イミノ)フェニルヨージナン(実施例3:段階a;388mg,1.04mmol)の溶液にトリフルオロメタンスルホン酸銅(II)(34.4mg,0.095mmol)を加えた。反応物は淡緑色になり、そしてRTで一晩攪拌した。反応混合物を濃縮し、そして次にEtOAcに溶解し、そして濾過して銅塩を除いた。フラッシュカラムクロマトグラフィー(ヘキサン中10%のEtOAc)により精製して所望の生成物を白色の固体(182mg,34%)として生成せしめた。1H−NMR(CDCl3):δ8.18(1H,t,J=1.9Hz),8.02−8.00(1H,m),8.01(1H,s),7.86−7.82(4H,m),7.48(1H,t,J=8.1Hz),7.31(1H,m),2.43(3H,s)。
.9;実測値:558.9、4−[S−(3−ブロモフェニル)−N−トシルスルホキシミノ]−5−メチルスルファニル−チオフェン−2−カルボキシミド酸メチルエステルの形成をもたらした。形成された4−(4−トルエンスルホニル−3−ブロモ−ベンゼンスルホキサミン)−5−メチルスルファニル−チオフェン−2−カルボキシミド酸メチルエステル中間体に、メタノール中のアンモニア(7N)(2mL,0.009mol)を加え、そして反応物を2時間攪拌した。これにギ酸アンモニウム(NH4HCO2)(6mg,0.09mol)を加え、そして反応物をさらに13時間攪拌した。溶媒を真空中で除き、その後にC18−HPLC(20分にわたって5〜60%のCH3CN/0.1%TFA 水)を続けた。最終化合物は、固体(1.8mg,30%)として単離された。1H−NMR(CD3OD):δ8.29(1H,s),8.08(1H,t,J=1.90Hz),8.04−8.01(1H,m),7.93−7.91(1H,m),7.71(2H,d,J=8.3Hz),7.56(1H,d,J=8.1Hz),7.32(2H,d,J=7.96Hz),2.71(3H,s),2.43(3H,s)。
4−(3−ブロモ−ベンゼンスルホキサミン)−5−メチルスルファニル−チオフェン−2−カルボキサミジン
4−(3−ブロモ−ベンゼンスルホキサミンアセトアミド)−5−メチルスルファニル−チオフェン−2−カルボキサミジン
−2−カルボキサミジン(実施例26:段階b;17mg,0.31mmol)の溶液にDMF(500mL)中のDIEA(27mL,0.16mmol)およびBoc2O(20mg,0.09mmol)を加えた。反応物をRTで12時間攪拌した。溶媒を真空中で除き、そしてヘキサンで研和してBoc2Oを除き、所望の生成物(14mg,70%)をもたらした。1H−NMR(CDCl3):δ8.24−8.23(1H,m),8.05−8.02(1H,d,J=7.9Hz),7.87(1H,s),7.71−7.69(1H,d,J=7.0Hz),7.41−7.36(1H,t,J=7.8Hz),2.93(3H,s),1.52(9H,s)。
5−ブロモ−4[S−(3−ブロモフェニル)−N−トシルスルホキシミノ]−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
8.06−8.04(1H,d,J=9.70Hz),7.94−7.95(1H,d,J=6.91Hz),7.74−7.72(2H,d,J=8.28Hz),7.59(1H,t,J=10.1Hz),7.34−7.32(2H,d,J=8.86Hz)。ESI−MS(m/z):C18H15Br2N3O3S3の計算値:574.86;実測値:575.9。
4−[S−[3−(2−トリルフェニル)フェニル]−N−トシルスルホキシミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
)−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩(実施例29:段階c;124mg,0.23mmol)の溶液にDIEA(0.72mL,.046mmol)およびBoc2O(60.2mg,0.27mmol)を加えた。反応物をRTで12時間攪拌した。反応は完了しておらず、従って、それを40℃に8時間加熱した。反応物を濃縮し、そしてフラッシュカラムクロマトグラフィー(40%のEtOAc/ヘキサン)により精製して表題化合物を固体(86mg,59%)として単離した。ESI−MS(m/z):C24H26BrN3O5S4の計算値:642.9;実測値:645.6。
4−[S−(3−ブロモフェニル)−N−ノシルスルホキシミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−スルホニル−3−ニトロ−ベンゼンスルホキシミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロ酢酸塩
):δ8.59−8.58(1H,m),8.49−8.47(1H,d,J=7.25Hz),8.37(1H,s),8.30−8.27(1H,d,J=6.9Hz),8.15−8.14(1H,m),8.07−8.05(1H,d,J=9.0Hz),7.95−7.93(1H,d,J=9.0Hz),7.83(1H,t,J=8.0Hz),7.58(1H,t,J=8.0Hz),2.71(3H,s)。
4−[S−(3−ブロモフェニル)−N−スルホニル−3−N−(5−メタンスルホニル−4−メチル−チアゾール−2−イル)−アセトアミドスルホキシミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−スルホニル−4−アミノフェニルスルホキシミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロ酢酸塩
l)の溶液にBoc2O(53mg,0.24mmol)を加え、そして反応物をRTで12時間攪拌した。反応物を濃縮し、EtOAcに溶解し、そして飽和NaHCO3で洗浄した。有機層を乾燥させ(MgSO4)、そして濃縮し、所望の生成物をもたらした。1H−NMR(CD3OD):δ8.30(2H,d,J=8.8Hz),8.18(2H,d,J=8.8Hz),8.01(1H,s),7.99(1H,8.0Hz),7.79(1H,d,J=7.2Hz),7.44(1H,t,J=8.0Hz),2.59(3H,s),1.53−1.46(9H,m)。
1H,d,J=9.8Hz),7.52(1H,t,J=8.0Hz),7.47−7.44(2H,m),6.58−6.56(2H,m),2.67(3H,s)。
4−[S−(3−ブロモフェニル)−N−スルホニル−3−アナリンスルホキシミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(6−シアノ−3−ピリジンカルボキサミド)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
バミン酸tert−ブチルエステル
4−[S−(3−ブロモフェニル)−N−(アシル−3−ピリジン−4−カルボキサミド)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−フェニルカルボニトリル)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−ベンズアミド)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−トリフルオロメチルベンゼン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−2−メチル−5−ニトロ−ベンゼン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
g,0.02mmol,実施例24:段階jにおいて製造したとおり)、4−メチル−3−ニトロ−ベンゼンスルホニルクロリド(10mg,0.04mmol)および2,6−ルチジン(25mL,0.21mmol)の反応、続いて実施例38:段階bに記載のとおりの同様のワークアップおよび精製により、2.0mgの表題化合物4−[S−(3−ブロモフェニル)−N−(スルホニル−2−メチル−5−ニトロ−ベンゼン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩を生成せしめた。1H−NMR(CD3OD):δ8.34−8.46(m,3H),8.11−8.14(m,1H),8.05(dm,1H,J=8.1Hz),7.95(dm,1H,J=8.0Hz),7.65−7.68(m,1H),7.59(t,1H,J=8.1Hz),2.89(s,3H)および2.65(s,3H)。ESI−MS(m/z):C19H17BrN4O5S4の計算値:588.9(M+1);実測値:588.9。
4−[S−(3−ブロモフェニル)−N−(スルホニル−5−メタンスルホニル−2−メチル−ベンゼン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−5−ブロモ−4−クロロ 3−ピリジン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−[スルホニル−7−(4−メチル−3,4−ジヒドロ−2H−ベンゾ[1,4]オキサジン)]−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−グアニジノベンゼン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−メタンスルホニルベンゼン)−スルホキサミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジントリフルオロ酢酸塩
4−[S−[3−(4−グアニジノ−6−メチル−フェニル)フェニル]−N−(3−ニトロベンゼン−スルホニル)スルホキシミノ]−5−メチルスルファニル−チオフェン−2−カルボキサミジンビストリフルオロ酢酸塩
トリル
[3−メチル−2−(4,4,5,5−テトラメチル−[1,3,2]ジオキサボロラン−2−イル)−5−(2−トリメチルシラニル−エトキシカルボニルアミノ)−フェニル]−カルバミン酸2−トリメチルシラニル−エチルエステル
4−[S−([6−メチル−4−(2−トリメチルシラニル−エトキシカルボニルアミ
ノ)−ビフェニル−2−イル]−カルバミン酸2−トリメチルシラニル−エチルエステル)−N−スルホニル−4−アナリンスルホキシミノ]−5−メチルスルファニル−チオフェン−2−カルバミン酸tert−ブチルエステル
錠剤製造
それぞれ25.0、50.0および100.0mgの活性化合物を含有する錠剤を以下に説明するように製造する:
25〜100mgの活性化合物を含有する用量のための錠剤
量−mg
活性化合物 25.0 50.0 100.00
微晶質セルロース 37.25 100.0 200.0
加工(modified) 37.25 4.25 8.5
フードコーンスターチ
ステアリン酸マグネシウム 0.50 0.75 1.5
静脈内液剤製造
上記の活性化合物の静脈内投与形態物を下記のとおり製造する:
活性化合物 0.5〜l0.0mg
クエン酸ナトリウム 5〜50mg
クエン酸 1〜15mg
塩化ナトリウム 1〜8mg
注射用水(USP) 1mlまで適量
C1sのインビトロ阻害
試薬:全てのバッファー塩は、Sigma Chemical Company(sSt.Louis,MO)から入手し、そして利用可能な最高純度のものであった。DTNBは、Pierce(Rockford,IL)から購入した。Z−Gly−Arg−S−Bzlは、Enzyme Systems Products(Livermore,CA)から購入した。活性化ヒトC1sは、Calbiochem(La Jolla,CA)から購入した。
MASP−2のインビトロ阻害
試薬:全てのバッファー塩は、Sigma Chemical Company(St.Louis,MO)から入手し、そして利用可能な最高純度のものであった。DTNBは、Pierce(Rockford,IL)から購入した。Z−Gly−Arg−S−Bzlは、Enzyme Systems Products(Livermore,CA)から購入した。自己活性化2鎖ヒトMASP−2(His標識,Cys300〜Phe686)は、昆虫細胞においてバキュロウイルス発現系から組織内で製造した。
以下の化合物は、C1sについて0.008〜6.0マイクロモル(μM)の範囲のKi値を有する:実施例3〜22、25〜28、30〜46。
Claims (24)
- 式I:
Zは−CO−、−SO2−、−SO2CH2−、−COCH2−、−CONH−又は直接結合であり、
ここでカルボニル炭素又は硫黄は窒素に結合しており;
QはC1-4アルキル、ハロ、アミノ、C1-6アルキルチオ、C2-6アルケニルチオ、C1-6アルコキシ、トリフルオロメチル、メチルスルホニル又はベンジルチオであり;
R1は水素、C1-4アルキル、アリール、ヘテロアリール、ベンゾ縮合ヘテロアリール、ベンゾ縮合ヘテロシクリルであり、水素を除くそれらはいずれも場合により:グアニジニル、ハロゲン、−CF3、−CN、−NO2、−NRdCORe、−CONRdRe、−NRdSO2Re、−SO2NRdRe、−NRdCONHRe、−Rd、−NRdRe、−CO2Rd、−SO2Rd又は1個のRdで置換されていることができるヘテロシクリルから独立して選ばれる1もしくは2個の置換基で置換されていることができ;
R2は水素、ハロゲン、アリール又はヘテロアリールであり、ここでアリール又はヘテロアリールは場合により:C(1−4)アルキル、−NRfRg、グアニジニルから独立して選ばれる最高で3個の置換基で置換されていることができ;
Aはアリール又はヘテロアリールであり;
Ra、Rb、Rc、Rd、Re、Rf及びRgは独立して水素、C1-4アルキル、C6-10アリール、C1-4ヒドロキシアルキル、C1-4アミノアルキル、モノ(C1-4)アルキルアミノ(C2-6)アルキル、ジ(C1-4)アルキルアミノ(C2-6)アルキル、カルボキシ(C1-4)アルキル、シアノ、ニトロ、アミノ、C1-4アルコキシ、ヒドロキシ又は−CO2Rwであり、ここで
Rwは水素、ヒドロキシ、C1-4アルコキシ、シアノ、C1-4アルコキシカルボニル、C1-4アルキル、C3-8シクロアルキル、フェニル又はベンジルである]
のラセミ又はホモキラル化合物あるいはその溶媒和物、水和物又は製薬学的に許容され得る塩。 - Qが−SC(1-4)アルキルであり;
Aがフェニルである
請求項1の化合物。 - Qが−SC(1-4)アルキルであり;
Aがフェニルであり;
R1が水素、C1-4アルキル、アリール、ヘテロアリール、ベンゾ縮合ヘテロアリール、ベンゾ縮合ヘテロシクリルであり、水素を除くそれらはいずれも場合により:グアニジニル、ハロゲン、−CF3、−CN、−NO2、NRdCORe、NRdSO2Re、NRdCONHRe、Rd、NH2、CO2Re、SO2Rd、ヘテロシクリルから独立して選ばれる1もしくは2個の置換基で置換されていることができる
請求項1の化合物。 - Qが−SC(1-4)アルキルであり;
Aがフェニルであり;
Ra、Rb及びRcが水素であり;
R1が水素、C1-4アルキル、フェニル、ピリジル、イミダゾリル、チアゾリル、フラニル、チエニル、ベンゾチアゾリル、ピラゾリル、ピリミジニル、3,4−ジヒドロ−2H−ベンゾ[1,4]オキサジン、ベンズイミダゾリル、ベンゾフラニル、インドリル、ベンゾチオフェニル又は1,3,4−オキサジアゾリルであり、水素を除くそれらはいずれも場合により:グアニジニル、ハロゲン、−CF3、−CN、−NO2、NRdCORe、NRdSO2Re、NRdCONHRe、Rd、NH2、CO2Re、SO2Rd、ヘテロシクリルから独立して選ばれる1もしくは2個の置換基で置換されていることができる
請求項1の化合物。 - 以下:
4−[S−(3−ブロモフェニル)−N−(2−ニトロベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(3−アセトアミドベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(3−{N,N−ビスメタンスルホニル}アミノベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(3−ウレイドベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(3−メタンスルホンアミドベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−{3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−ベンゼン−スルホニル}スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−{3−(オキサゾール−5−イル−ベンゼン−スルホニル}スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモ−ベンゼンスルホニル)−N−(m−スルホニル安息香酸)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモ−ベンゼンスルホニル)−N−(p−スルホニル安息香酸)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−トシルスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
5−ブロモ−4[S−(3−ブロモフェニル)−N−トシルスルホキシイミノ]−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−ノシルスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−スルホニル−3−ニトロ−ベンゼンスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−スルホニル−4−アミノフェニルスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロアセテート;4−[S−(3−ブロモフェニル)−N−スルホニル−3−アニリンスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−フェニルカルボニトリル)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−ベンズアミド)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−トリフルオロメチルベンゼン)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−2−メチル−5−ニトロ−ベンゼン)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−5−メタンスルホニル−2−メチル−ベンゼン)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−グアニジノベンゼン)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート;及び
4−[S−(3−ブロモフェニル)−N−(スルホニル−3−メタンスルホニルベンゼン)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート
よりなる群から選ばれる化合物。 - 4−[S−(3−ブロモフェニル)−N−p−トリル−ホルムアミド]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート
である化合物。 - 以下:
4−[S−(3−ブロモフェニル)−N−ベンズアミド]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−3−ニトロ−ベンズアミド]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−3−アミノ−ベンズアミド]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(6−シアノ−3−ピリジンカルボキシアミド)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;及び
4−[S−(3−ブロモフェニル)−N−(アシル−3−ピリジン−4−カルボキシアミド)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート
よりなる群から選ばれる化合物。 - 以下:
4−[S−(3−ブロモフェニル)−N−(フェニルメタン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(メタンスルホニル)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;及び
4−[S−(3−ブロモフェニル)−N−({2−アミノフェニル}メタン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート
よりなる群から選ばれる化合物。 - 以下:
4−[S−[3−(2−アミノ−4−グアニジノ−6−メチル−フェニル)フェニル]−N−(3−ウレイドベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート;
4−[S−[3−(2−トリルフェニル)フェニル]−N−トシルスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−[3−(2−アミノ−4−グアニジノ−6−メチル−フェニル)フェニル]−N−(4−ウレイドベンゼン−スルホニル)スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート;及び
4−[S−[3−(4−グアニジノ−6−メチル−フェニル)フェニル]−N−(3−ニトロベンゼン−スルホニル)スルホキシイミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート
よりなる群から選ばれる化合物。 - 以下:
4−[S−(3−ブロモフェニル)−N−(2−ピリジンスルホニル)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(m−スルホニルピリジル)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−スルホニル−3−N−(5−メタンスルホニル−4−メチル−チアゾール−2−イル)−アセトアミドスルホキシイミノ]−5−メチルスルファニル−チオフェン−2−アミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−N−(スルホニル−5−ブロモ−4−クロロ 3−ピリジン)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート;及び
4−[S−(3−ブロモフェニル)−N−[スルホニル−7−(4−メチル−3,4−ジヒドロ−2H−ベンゾ[1,4]オキサジン)]−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジンビストリフルオロアセテート
よりなる群から選ばれる化合物。 - 以下:
4−[S−(3−ブロモフェニル)−N−(フェニル)−スルホキシアミノ]−5−メチルスルファニル−チオフェン−2−カルボキシアミジントリフルオロアセテート;
4−[S−(3−ブロモフェニル)−スルホキシイミノ]−5−メチルスルファニル−チオフェン−2−カルバミン酸tert−ブチルエステル;及び
4−(3−ブロモ−ベンゼンスルホキシアミン)−5−メチルスルファニル−チオフェン−2−カルボキシアミジン
よりなる群から選ばれる化合物。 - 4−(3−ブロモ−ベンゼンスルホキシアミンアセトアミド)−5−メチルスルファニル−チオフェン−2−カルボキシアミジン
である化合物。 - 請求項1の化合物及び製薬学的に許容され得る担体又は希釈剤を含んでなる製薬学的組成物。
- 請求項1の化合物を有効成分として含有する、炎症、組織損傷もしくは自己免疫疾患;クローン病の腸管炎症、再狭窄もしくは乾癬;自己免疫疾患;アジソン病、I型糖尿病、橋本甲状腺炎、全身性エリテマトーデスの糸球体腎炎及び皮膚病変、他の糸球体腎炎、水疱性類天疱瘡、疱疹状皮膚炎、グッドパスチャー症候群、グレーヴズ病、重症筋無力症、インスリン抵抗性、自己免疫性溶血性貧血、自己免疫性血小板減少性紫斑病、免疫複合体−誘導脈管炎糸球体腎炎、II型コラーゲン−誘導関節炎、慢性関節リウマチもしくはアレルギー性神経炎;重症筋無力症(MG)、慢性関節リウマチもしくは全身性エリテマトーデス;神経変性疾患;成人呼吸促進症候群;敗血症性ショック;又は遺伝性血管性水腫、発作性夜間血色素尿症、創傷治癒、脳傷害、喘息、血液透析、感染、皮膚病、炎症性腸疾患、骨粗しょう症、変形性関節症、熱傷(thermal injury)(熱傷(burns)及び凍傷)、溶血性貧血もしくは心肺バイパスにおけるポンプ後症候群(post pump syndrome)の処置剤。
- 該炎症又は組織損傷が発作、心筋梗塞、出血性ショック又は手術あるいはそれらの組み合わせに続いて起こるものである請求項14の処置剤。
- 臓器又は移植片の移植の前、その間又はその後に哺乳類に投与される請求項14の処置剤。
- (1)IL−2を用いる哺乳類の処置、(2)哺乳類における骨髄移植又は(3)哺乳類における膵臓炎の開始の前、その間又はその後に、IL−2処置、骨髄移植又は膵臓炎の毒性及び副作用を減少させるために哺乳類に投与される請求項14の処置剤。
- 該神経変性疾患が多発性硬化症(MS)、ギャン−バレー症候群(GBS)、ミラー−フィッシャー症候群(MFS)、アルツハイマー病(AD)又は変種クロイツフェルト−ヤーコブ病(variant Creutzfeldt−Jakob disease)(vCJD)である請求項14の処置剤。
- 請求項1の化合物を有効成分として含有する、患者における移植組織又は移植片の拒絶を減少させるための薬剤。
- 患者に心不全、糖尿病、発作、パーキンソン病、アルツハイマー病、肝臓病、腎臓病、熱傷及び創傷よりなる群から選ばれる障害のための治療の一部として移植組織又は移植片が与えられる請求項19の薬剤。
- 細胞移植の細胞が幹細胞、一次細胞、組織培養に由来する細胞、ランゲルハンス島細胞、インスリンを発現する細胞、グルコース−調節ホルモンを発現する細胞又は糖尿病の処置に有用な因子を発現する細胞である請求項20の薬剤。
- 請求項1の化合物からなる、臓器を該化合物と接触させて、臓器保存溶液中における臓器の補体活性化を妨げるための薬剤。
- 請求項1の化合物からなる、医学的装置を該化合物と接触させて、患者中への医学的装置の挿入に反応する補体活性化を妨げるための薬剤。
- 医学的装置がステント、プロテーゼ、人工臓器又は人工関節である請求項23の薬剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66251805P | 2005-03-16 | 2005-03-16 | |
US60/662,518 | 2005-03-16 | ||
PCT/US2006/009196 WO2006101860A1 (en) | 2005-03-16 | 2006-03-14 | Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008533156A JP2008533156A (ja) | 2008-08-21 |
JP5081807B2 true JP5081807B2 (ja) | 2012-11-28 |
Family
ID=36645595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008501978A Expired - Fee Related JP5081807B2 (ja) | 2005-03-16 | 2006-03-14 | 補体−媒介疾患及び状態の処置のための新規なチオフェンスルホキシイミン |
Country Status (10)
Country | Link |
---|---|
US (2) | US7385066B2 (ja) |
EP (1) | EP1863785B1 (ja) |
JP (1) | JP5081807B2 (ja) |
KR (1) | KR20080002832A (ja) |
AT (1) | ATE450522T1 (ja) |
AU (1) | AU2006227778A1 (ja) |
CA (1) | CA2601523A1 (ja) |
DE (1) | DE602006010834D1 (ja) |
MX (1) | MX2007011293A (ja) |
WO (1) | WO2006101860A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8558002B2 (en) | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
EP2099757B1 (en) * | 2006-11-16 | 2014-06-25 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
US20090324585A1 (en) * | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
JP5793188B2 (ja) | 2011-05-13 | 2015-10-14 | 国立大学法人 東京大学 | 自己免疫疾患治療及び予防薬としてのctrp6 |
JP6538561B2 (ja) | 2012-10-25 | 2019-07-03 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体C1s抗体とそれらの用途 |
CA2889197A1 (en) | 2012-11-02 | 2014-05-08 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
UY36547A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
EP3280440B1 (en) | 2015-04-06 | 2022-11-16 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
EP3331870B1 (de) | 2015-08-07 | 2021-06-16 | Bayer CropScience Aktiengesellschaft | 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel |
CN106518734B (zh) * | 2016-10-21 | 2018-06-26 | 丽水学院 | 一种用硫酚或硫醇制备亚磺酸酯的方法 |
CN108191792B (zh) * | 2017-12-28 | 2020-03-27 | 上海博志研新药物技术有限公司 | 一种氢溴酸沃替西汀及其中间体的制备方法 |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
US20220185815A1 (en) | 2019-03-06 | 2022-06-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
CN115052862A (zh) * | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
MX2022006750A (es) | 2019-12-04 | 2022-06-14 | Omeros Corp | Inhibidores de masp-2 y metodos de uso. |
WO2021113686A1 (en) * | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
WO2021113698A1 (en) * | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
JP2023542949A (ja) * | 2020-09-23 | 2023-10-12 | アキリオン ファーマシューティカルズ, インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025506A (en) * | 1973-12-14 | 1977-05-24 | Pfizer Inc. | Broad spectrum antibiotics |
WO2000061574A2 (de) | 1999-04-09 | 2000-10-19 | Basf Aktiengesellschaft | Verfahren zur herstellung von thiophenyl-amidinen |
TR200102913T2 (tr) * | 1999-04-09 | 2002-01-21 | Basf Aktiengesellschaft | Tam proteazların düşük moleküler ağırlıklı inhibitörleri. |
WO2001098365A2 (en) * | 2000-06-21 | 2001-12-27 | Zymogenetics, Inc. | Peptide and polypeptide inhibitors of complement c1s |
-
2006
- 2006-03-14 DE DE602006010834T patent/DE602006010834D1/de active Active
- 2006-03-14 WO PCT/US2006/009196 patent/WO2006101860A1/en active Application Filing
- 2006-03-14 EP EP06738277A patent/EP1863785B1/en not_active Not-in-force
- 2006-03-14 AU AU2006227778A patent/AU2006227778A1/en not_active Abandoned
- 2006-03-14 MX MX2007011293A patent/MX2007011293A/es active IP Right Grant
- 2006-03-14 CA CA002601523A patent/CA2601523A1/en not_active Abandoned
- 2006-03-14 US US11/375,503 patent/US7385066B2/en active Active
- 2006-03-14 JP JP2008501978A patent/JP5081807B2/ja not_active Expired - Fee Related
- 2006-03-14 AT AT06738277T patent/ATE450522T1/de not_active IP Right Cessation
- 2006-03-14 KR KR1020077023582A patent/KR20080002832A/ko not_active Application Discontinuation
-
2008
- 2008-04-03 US US12/061,873 patent/US7868023B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008533156A (ja) | 2008-08-21 |
ATE450522T1 (de) | 2009-12-15 |
WO2006101860A1 (en) | 2006-09-28 |
DE602006010834D1 (de) | 2010-01-14 |
MX2007011293A (es) | 2008-03-18 |
EP1863785A1 (en) | 2007-12-12 |
AU2006227778A1 (en) | 2006-09-28 |
US7868023B2 (en) | 2011-01-11 |
CA2601523A1 (en) | 2006-09-28 |
US20070066667A1 (en) | 2007-03-22 |
KR20080002832A (ko) | 2008-01-04 |
US7385066B2 (en) | 2008-06-10 |
US20080255108A1 (en) | 2008-10-16 |
EP1863785B1 (en) | 2009-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5081807B2 (ja) | 補体−媒介疾患及び状態の処置のための新規なチオフェンスルホキシイミン | |
US6515002B2 (en) | Compounds and compositions for treating C1s-mediated diseases and conditions | |
US7138530B2 (en) | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | |
CA2901637C (en) | Multisubstituted aromatic compounds as serine protease inhibitors | |
US6562840B1 (en) | Heteroaryl amidines, methylamidines and guanidines, and the use thereof as protease inhibitors | |
US20040229889A1 (en) | HDAC inhibitor | |
EP1054886B1 (en) | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors | |
CA2337588A1 (en) | Oxamides as impdh inhibitors | |
JP2009542641A (ja) | 新規ピリジン類縁体 | |
JP2009542643A (ja) | 新規ピリジン類似体 | |
EP1015449B1 (en) | (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors | |
WO2019142053A2 (en) | Therapeutic inhibitory compounds | |
JPH0753500A (ja) | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 | |
KR20220156890A (ko) | Phd 억제제 화합물, 조성물, 및 용도 | |
CN108383828A (zh) | 作为趋化因子受体调节剂的新的1,2-双-磺酰胺衍生物 | |
RU2184110C2 (ru) | Производные нитрометилтиобензола, способ их получения (варианты) и фармацевтическая композиция | |
TW202412772A (zh) | 作為選擇性組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物 | |
CZ341799A3 (cs) | Deriváty hydroxamové kyseliny substituované aryl- nebo heteroarylsulfonamidem, způsob jejich přípravy a jejich použití jako léčivých přípravků |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120828 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120903 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150907 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5081807 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |